These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22167408)

  • 1. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
    Jamal-Hanjani M; Spicer J
    Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
    Bartolotti M; Franceschi E; Brandes AA
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1429-35. PubMed ID: 23249107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
    Zhang J; Yu J; Sun X; Meng X
    Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.
    Berger LA; Riesenberg H; Bokemeyer C; Atanackovic D
    Lung Cancer; 2013 Jun; 80(3):242-8. PubMed ID: 23453646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
    Kotsakis A; Georgoulias V
    Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
    Pan M; Santamaria M; Wollman DB
    Nat Clin Pract Oncol; 2007 Oct; 4(10):603-7. PubMed ID: 17898810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain metastasis responding to gefitinib alone.
    Poon AN; Ho SS; Yeo W; Mok TS
    Oncology; 2004; 67(2):174-8. PubMed ID: 15539923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
    Fang L; Sun X; Song Y; Zhang Y; Li F; Xu Y; Ma S; Lin N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):873-7. PubMed ID: 26310285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
    Kuiper JL; Smit EF
    Lung Cancer; 2013 Apr; 80(1):102-5. PubMed ID: 23375403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.
    Chen Y; Wang M; Zhong W; Zhao J
    Lung Cancer; 2013 Nov; 82(2):313-8. PubMed ID: 24011632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
    Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L
    Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
    Kobayashi T; Takeda M; Marumo S; Koshimo Y; Teranishi T; Higami Y; Kato M
    Lung Cancer; 2013 Apr; 80(1):109-11. PubMed ID: 23279871
    [No Abstract]   [Full Text] [Related]  

  • 17. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
    Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim DW; Ahn MJ; Yang JC; Zhang X
    Sci Transl Med; 2016 Dec; 8(368):368ra172. PubMed ID: 27928026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
    Togashi Y; Masago K; Fukudo M; Terada T; Fujita S; Irisa K; Sakamori Y; Kim YH; Mio T; Inui K; Mishima M
    J Thorac Oncol; 2010 Jul; 5(7):950-5. PubMed ID: 20479691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Liu SF; Huang KT; Chen HC; Chang YC; Lin MC
    PLoS One; 2016; 11(2):e0149722. PubMed ID: 26894507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.
    Sekine A; Satoh H
    Med Oncol; 2017 Jul; 34(7):121. PubMed ID: 28555261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.